Review on Antiviral Activity of Molnupiravir Against COVID-19

Authors

  • Sumit Agarwal Research Scholar, Bhagwant University, Ajmer, Rajasthan, India
  • Rajasekaran.S Professor cum HOD department of Pharmacology, Al-azhar College of pharmacy, Thodupuzha, Idukki district, Kerala, India

Keywords:

COVID-19, molnupiravir, antiviral, orally bioavailable, safety SARS-CoV-2.

Abstract

The global COVID-19 pandemic is having devastating impacts on human health and economic development. To date, theWorld Health Organization (WHO) has received reports of more than 412 million confirmed cases of COVID-19, with over 5 million deaths. Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. Most of the preclinical studies and available clinical trials showed a favorable short-term safety profile of molnupiravir; however, given its possible genotoxic effects, further trials are required to confirm the long-term efficacy and safety of molnupiravir in patients with COVID-19.

Downloads

Published

2023-03-16

Issue

Vol. 9 No. 1 (2023): Vol 9. No 1 (2023) Volume - 9 Issue - 1

Section

Articles

License

Rights and reuse terms depend on the individual article record. Articles accepted on or after 8 September 2026 are licensed under Creative Commons Attribution 4.0 International (CC BY 4.0), provided appropriate credit is given, a link to the licence is supplied and changes are indicated. Earlier content remains governed by the rights and licence notice applicable to that article and is not retrospectively relicensed by this policy. Third-party material identified under a different notice is excluded from the journal licence.